ICI 192605

产品名称：

117621-64-4
ICI 192605
(4Z)-rel-
4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid
4-Hexenoic acid
6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-

产品介绍：

产品说明

包装

5, 25 mg in glass bottle

生化/生理作用

ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release.

特点和优势

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

基本信息

经验(实验)分子式	C₂₂H₂₃ClO₅
分子量	402.87
MDL编号	MFCD00673936
PubChem化学物质编号	329815367

产品性质

质量水平	100
测定	≥98% (HPLC)
形式	powder
颜色	white to tan
溶解性	DMSO: ≥20 mg/mL
创始人	AstraZeneca
储存温度	−20℃
SMILES string	OC(=O)CC\C=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl
InChI	1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1
InChI key	WHUIENZXNGAHQI-YGPRPMEGSA-N

安全信息

象形图
警示用语：	Warning
危险声明	H302 - H410
预防措施声明	P273 - P501
危险分类	Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
储存分类代码	11 - Combustible Solids
WGK	WGK 3
闪点(F)	Not applicable
闪点(C)	Not applicable